↓ Skip to main content

Gene Therapy of Solid Cancers

Overview of attention for book
Cover of 'Gene Therapy of Solid Cancers'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy
  3. Altmetric Badge
    Chapter 2 Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model.
  4. Altmetric Badge
    Chapter 3 MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy.
  5. Altmetric Badge
    Chapter 4 Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis
  6. Altmetric Badge
    Chapter 5 Oncoleaking: Use of the Pore-Forming Clostridium perfringens Enterotoxin (CPE) for Suicide Gene Therapy
  7. Altmetric Badge
    Chapter 6 iCaspase 9 Suicide Gene System.
  8. Altmetric Badge
    Chapter 7 p53-Encoding pDNA Purification by Affinity Chromatography for Cancer Therapy
  9. Altmetric Badge
    Chapter 8 A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic.
  10. Altmetric Badge
    Chapter 9 Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
  11. Altmetric Badge
    Chapter 10 RNA Interference for Antimetastatic Therapy
  12. Altmetric Badge
    Chapter 11 STAT3 Decoy ODN Therapy for Cancer.
  13. Altmetric Badge
    Chapter 12 Oncolytic Viral Therapy Using Reovirus
  14. Altmetric Badge
    Chapter 13 Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring
  15. Altmetric Badge
    Chapter 14 Back to the Future: Are Tumor-Targeting Bacteria the Next-Generation Cancer Therapy? - PubMed - NCBI
  16. Altmetric Badge
    Chapter 15 Ethics of Cancer Gene Transfer Clinical Research
  17. Altmetric Badge
    Chapter 16 Planning an Academic Clinical Trial
  18. Altmetric Badge
    Chapter 17 Production of Plasmid DNA as Pharmaceutical
  19. Altmetric Badge
    Chapter 18 Minicircle: Next Generation DNA Vectors for Vaccination.
  20. Altmetric Badge
    Chapter 19 A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
  21. Altmetric Badge
    Chapter 20 Antiangiogenic Metargidin Peptide (AMEP) Gene Therapy in Disseminated Melanoma.
  22. Altmetric Badge
    Chapter 21 Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
Attention for Chapter 9: Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
Chapter number 9
Book title
Gene Therapy of Solid Cancers
Published in
Methods in molecular biology, January 2015
DOI 10.1007/978-1-4939-2727-2_9
Pubmed ID
Book ISBNs
978-1-4939-2726-5, 978-1-4939-2727-2
Authors

Jaschinski, Frank, Korhonen, Hanna, Janicot, Michel, Frank Jaschinski, Hanna Korhonen, Michel Janicot

Abstract

Transforming growth factor beta isoforms (TGF-β1, -β2, and -β3) are cytokines associated with a wide range of biological processes in oncology including tumor cell invasion and migration, angiogenesis, immunosuppression, as well as regulation of tumor stem cell properties. Hence, blocking the TGF-β signaling pathways may have a multifold therapeutic benefit for the treatment of solid tumors. Here, we describe the identification and selection processes for the development of highly potent and selective chemically modified antisense oligodeoxynucleotides (fully phosphorothioate locked nucleic acid gapmers) allowing effective and selective suppression of TGF-β isoform expression in cell-based assays and in vivo preclinical models.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 20%
Other 1 10%
Lecturer > Senior Lecturer 1 10%
Student > Bachelor 1 10%
Student > Postgraduate 1 10%
Other 0 0%
Unknown 4 40%
Readers by discipline Count As %
Agricultural and Biological Sciences 3 30%
Biochemistry, Genetics and Molecular Biology 2 20%
Medicine and Dentistry 1 10%
Unknown 4 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2015.
All research outputs
#20,280,315
of 22,813,792 outputs
Outputs from Methods in molecular biology
#9,908
of 13,118 outputs
Outputs of similar age
#295,827
of 353,098 outputs
Outputs of similar age from Methods in molecular biology
#636
of 997 outputs
Altmetric has tracked 22,813,792 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,118 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,098 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 997 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.